切换至 "中华医学电子期刊资源库"
高级检索
中华细胞与干细胞杂志(电子版)

中华细胞与干细胞杂志(电子版) ›› 2020, Vol. 10 ›› Issue (01) : 44 -48. doi: 10.3877/cma.j.issn.2095-1221.2020.01.008

所属专题： 文献；

论著

钙结合蛋白S100A16对胰岛素抵抗的作用研究
沈歌前1, 阚敬保1, 张日华1, 刘云1,†()   
  1. 1. 210029　南京医科大学第一附属医院老年医学科
  • 收稿日期:2019-11-22 出版日期:2020-02-01
  • 通信作者: 刘云
  • 基金资助:
    国家自然科学基金(81600001)

Effects of calcium binding protein S100A16 on promoting insulin resistance

Geqian Shen1, Jingbao Kan1, Rihua Zhang1, Yun Liu1,†()   

  1. 1. Department of Geriatrics, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
  • Received:2019-11-22 Published:2020-02-01
  • Corresponding author: Yun Liu
  • About author:
    Corresponding author:Liu Yun, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

沈歌前, 阚敬保, 张日华, 刘云. 钙结合蛋白S100A16对胰岛素抵抗的作用研究[J]. 中华细胞与干细胞杂志(电子版), 2020, 10(01): 44-48.

Geqian Shen, Jingbao Kan, Rihua Zhang, Yun Liu. Effects of calcium binding protein S100A16 on promoting insulin resistance[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2020, 10(01): 44-48.

目的

探究钙结合蛋白S100A16在胰岛素抵抗中的作用。

方法

用S100A16抗体进行免疫沉淀，然后用蛋白质谱分析寻找与S100A16相互作用的蛋白。实验1转染Vector质粒的HepG2细胞作为对照，用转染shRNA质粒、S100A16过表达质粒干预作为处理组。实验2以慢性胰岛素刺激细胞构建胰岛素抵抗模型，采用转染shRNA质粒的细胞作为对照，用未转染和转染Vector质粒干预作为处理组。实验3以不做任何处理的细胞作为对照，在胰岛素抵抗模型中用吡格列酮干预作为处理组。Western blot检测相关蛋白的表达水平。组间比较采用成组t检验。

结果

与转染Vector质粒比较，转染S100A16过表达质粒中胎球蛋白A表达（1.39±0.54比2.85±0.25）水平上调（P < 0.05）；与转染Vector质粒比较，转染shRNA质粒胎球蛋白A蛋白表达（0.36±0.03比0.20±0.03）水平降低（P < 0.01）。在胰岛素抵抗条件下，与转染shRNA质粒的细胞比较，未转染和转染Vector质粒的IRS-2蛋白表达（0.11±0.04比1.65±0.48）水平上调（P < 0.01）；与不做任何处理的细胞比较，用吡格列酮处理的细胞IRS-2表达（0.26±0.11比0.52±0.05）水平上升（P < 0.01）。

结论

S100A16在HepG2细胞中通过胎球蛋白A促进胰岛素抵抗。

关键词: S100A16, 胰岛素抵抗, 胎球蛋白A, 胰岛素受体底物2, HepG2细胞
Objective

To explore the effects of S100A16, a calcium-binding protein on insulin resistance.

Methods

Immunoprecipitation was performed with S100A16 antibody, and mass spectrometry was used to find proteins interacting with S100A16. HepG2 cells transfected with shRNA plasmids or S100A16 overexpression plasmids were defined as experimental group 1 and HepG2 cells transfected with vector plasmids as control group 1. Chronic insulin stimulation was done to the cells to establish insulin resistance models, in which cells transfected with shRNA plasmids were experimental group 2. Those not transfected or transfected with vector plasmids were set to be control group 2. Cells treated with pioglitazone were experimental group 3 and those without pioglitazone treatment were control group 3 in insulin resistance group. The expression levels of relevant proteins were detected by Western blot. Unpaired t test was used for statistical analysis.

Results

Compared with control group 1, the expression of Fetuin A in overexpressed S100A16 group in experimental group 1 was increased significantly (1.39±0.54 vs 2.85±0.25, P< 0.05) , while the expression of Fetuin A in shRNA group in experimental group 1 was significantly decrease (0.36±0.03 vs 0.20±0.03, P< 0.01) . In contrast to control group 2, the expression of IRS-2 (insulin receptor substrate-2) in experimental group 2 was significantly increased under the condition of insulin resistance (0.11±0.04 vs 1.65±0.48, P< 0.01) . And compared with control group 3, the expression of IRS-2 in experimental group 3 was obviously increased (0.26±0.11 vs 0.52±0.05, P< 0.01) .

Conclusion

S100A16 promotes insulin resistancein HepG2 cells via Fetuin A.

Key words: S100A16, Insulin resistance, Fetuin A, Insulin Receptor Substrate-2, HepG2 cells
图1 胎球蛋白A的质谱
图2 S100A16调节胎球蛋白A以及IRS-2的表达
图3 S100A16在胰岛素抵抗条件下抑制IRS-2的表达
图4 S100A16通过胎球蛋白A下调IRS-2的表达
1
Moore BW. A soluble protein characteristic of the nervous system[J]. Biochem Biophys Res Commun, 1965, 19(6):739-744.
2
Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer[J]. Nat Rev Cancer, 2015, 15(2):96-109.
3
童佩, 奚玲, 杨洁, 等. S100A16基因敲除小鼠模型的构建与鉴定[J]. 南京医科大学学报(自然科学版), 2017, 37(5):549-553.
4
Liu Y, Zhang R, Xin J, et al. Identification of S100A16 as a novel adipogenesis promoting factor in 3T3-L1 cells[J]. Endocrinology, 2011, 152(3):903-911.
5
Ochieng J, Nangami G, Sakwe A, et al. Impact of Fetuin-A (AHSG) on tumor progression and type 2 diabetes[J]. Int J MolSci, 2018, 19(8).pii: E2211.
6
Haukeland JW, Dahl TB, Yndestad A, et al. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies[J]. Eur J Endocrinol, 2012, 166(3):503-510.
7
阚敬保, 沈歌前, 杨洁, 等. S100钙结合蛋白A16通过内质网应激促进HepG2细胞脂肪合成[J]. 生理学报, 2019, 71(2):279-286.
8
Ou HY, Wu HT, Hung HC, et al. Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance[J]. Endocrinology, 2012, 153(7):2974-2984.
9
童佩. 钙结合蛋白S100A16基因敲除小鼠的构建以及S100A16对高脂饮食诱导下肥胖小鼠糖脂代谢的影响及其机制研究[D]. 南京: 南京医科大学, 2017.
10
Ochi A, Mori K, Emoto M, et al. Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression[J]. PLoS One, 2014, 9(2): e88704.
11
Mori K, Emoto M, Araki T, et al. Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus[J]. Metabolism, 2008, 57(9):1248-1252.
12
Honma M, Sawada S, Ueno Y, et al. Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers[J]. Int J Obes (Lond), 2018, 42(9):1544-1555.
13
Landis J, Shaw LM. Insulin receptor substrate 2-mediated phosphatidylinositol 3-kinase signaling selectively inhibits glycogen synthase kinase 3β to regulate aerobic glycolysis[J]. J Biol Chem, 2014, 289(26):18603-18613.
14
Clark SF, Molero JC, James DE. Release of insulin receptor substrate proteins from an intracellular complex coincides with the development of insulin resistance[J]. J Biol Chem, 2000, 275(6):3819-3826.
15
Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications[J].Hepatology, 2010, 51(2):679-689.
16
Stefan N, Häring HU. The role of hepatokines in metabolism[J]. Nat Rev Endocrinol, 2013, 9(3):144-152.
17
Li D, Zhang R, Zhu W, et al. S100A16 inhibits osteogenesis but stimulates adipogenesis[J]. Mol Biol Rep, 2013, 40(5):3465-3473.
[1] 郭庆, 李冠琳, 刘慧, 魏炜, 于洋, 张纯. 脂肪间充质干细胞治疗糖尿病及其慢性并发症的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(01): 58-62.
[2] 刘琴, 袁蕾. lncRNA GAS5对胰岛素抵抗模型中卵巢颗粒细胞功能的影响及相关机制研究[J]. 中华细胞与干细胞杂志(电子版), 2021, 11(03): 137-145.
[3] 龚宇蓉, 蔡丹, 翁明哲. 术前口服碳水化合物对ERCP术后患者胰岛素抵抗及心理康复的影响[J]. 中华肝脏外科手术学电子杂志, 2020, 09(04): 343-346.
[4] 朱国英, 陈利, 丁永年, 杨长青, 朱风尚. 重视脂肪胰的基础和临床研究[J]. 中华消化病与影像杂志(电子版), 2022, 12(03): 129-132.
[5] 靳潇潇, 郑聪, 何文强. 肾结石与高血压关系的研究进展[J]. 中华临床医师杂志(电子版), 2022, 16(12): 1284-1288.
[6] 王研, 丁旭, 黄艳红. 维生素D对多囊卵巢综合征患者生育影响的研究进展[J]. 中华临床医师杂志(电子版), 2021, 15(05): 393-396.
[7] 朱建琴, 李国青, 缪逸. 正常体质量人群简单胰岛素抵抗指数与高尿酸血症的相关性研究[J]. 中华临床医师杂志(电子版), 2020, 14(10): 808-812.
[8] 李靖, 刘芙蓉. 正常高值血压男性血清chemerin水平与代谢指标的相关性研究[J]. 中华临床医师杂志(电子版), 2020, 14(01): 39-42.
[9] 张金娜, 盖家宁, 李影. 脂质运载蛋白2在肥胖症及相关疾病中的作用研究进展[J]. 中华肥胖与代谢病电子杂志, 2023, 09(01): 50-54.
[10] 于莉莉, 李艳花, 张朝阳, 邓一鸣, 林剑泷, 冯志伟. 不同组织慢性炎症的特点及其在胰岛素抵抗发展中的作用[J]. 中华肥胖与代谢病电子杂志, 2021, 07(04): 260-265.
[11] 吴勇, 林伟平, 李斯毅, 杨立文, 刘滢. 糖尿病肾病患者血清白脂素水平与肾功能和糖代谢指标的相关性研究[J]. 中华肥胖与代谢病电子杂志, 2021, 07(02): 104-107.
[12] 黄炎驱, 林延明, 余丹红. 不同通量血液透析联合血液透析滤过对胰岛素抵抗尿毒症患者的疗效比较[J]. 中华肥胖与代谢病电子杂志, 2021, 07(01): 36-40.
[13] 许庆玲, 张淑欣, 吴楚姗, 郑荣秀. 肥胖儿童黑棘皮病严重程度与胰岛素抵抗的相关性研究[J]. 中华肥胖与代谢病电子杂志, 2021, 07(01): 30-35.
[14] 李影, 付真真, 周红文, 梁辉, 管蔚. 袖状胃切除术早期对肥胖症患者血清白脂素水平的影响[J]. 中华肥胖与代谢病电子杂志, 2020, 06(04): 227-232.
[15] 梁俏丽, 陈静娟, 周锋, 邵燕, 王玉凯, 章成国. 胰岛素抵抗与缺血性脑卒中关系的研究进展[J]. 中华脑血管病杂志(电子版), 2022, 16(02): 120-124.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号